Trial NCT04776850

View at ClinicalTrials.gov 
Org. Study IDs: 2020-0952
Secondary IDs: 2020-0952 NCI-2021-00365

Last trial update was posted on 2023-02-21

MeSH Interventions

Antibodies Antibodies, Monoclonal Antilymphocyte Serum Antineoplastic Agents, Immunological BB 1101 Bortezomib Busulfan Cyclophosphamide Dexamethasone Dexamethasone acetate Fludarabine Fludarabine phosphate Immunoglobulins Immunoglobulins, Intravenous Mycophenolic Acid Rho(D) Immune Globulin Rituximab Tacrolimus Thymoglobulin gamma-Globulins

MeSH Conditions

Anemia, Sickle Cell Hemoglobinopathies Thalassemia beta-Thalassemia

Other Conditions

Beta Thalassemia Major Sickle Beta 0 Thalassemia Sickle Beta Plus Thalassemia Sickle Beta Thalassemia Sickle Cell Disease Sickle Cell-SS Disease

Stopping Reasons

Competing protocol opened in Adult SCT that will include pediatric patients and is now multi-center. No patients enrolled on study.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID